Related Experiment Videos
Inflammatory reaction in familial Mediterranean fever (FMF) before and with colchicine therapy
Abstract:
The familial mediterranean fever (FMF) is an inherited, autosomal, recessive disorder which occurs predominantly but not exclusively in Sephardic Jews. It is characterized by a total increase of blood complement components, particularly C4, without any molecular anomaly and associated with an increase in other inflammatory proteins. With colchicine therapy, the symptomatology observed regresses or diminishes and onset of amyloidosis is prevented but the inflammatory and biochemical syndrome persists.
Insights
Familial Mediterranean Fever (FMF) is an inherited disorder causing increased inflammatory proteins. Colchicine therapy reduces symptoms and prevents amyloidosis but doesn't resolve the underlying biochemical changes.
Area of Science:
- Genetics
- Immunology
- Rheumatology
Background:
- Familial Mediterranean Fever (FMF) is an inherited, autosomal, recessive disorder.
- It predominantly affects Sephardic Jewish populations but is not exclusive to them.
Purpose of the Study:
- To describe the clinical and biochemical characteristics of FMF.
- To evaluate the efficacy of colchicine in managing FMF symptoms and preventing complications.
Main Methods:
- Observational study of FMF patients.
- Biochemical analysis of blood complement components and inflammatory proteins.
- Clinical assessment of symptom response to colchicine therapy.
Main Results:
- FMF is characterized by elevated blood complement components, especially C4, and other inflammatory proteins.
- Colchicine therapy leads to regression or diminution of FMF symptomatology.
- Colchicine effectively prevents the onset of amyloidosis in FMF patients.
Conclusions:
- Colchicine is an effective treatment for managing FMF symptoms and preventing amyloidosis.
- Despite symptomatic improvement, the underlying inflammatory and biochemical syndrome in FMF persists with colchicine therapy.